This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo
Clinical Summary

Novel cream shows benefit in facial seborrheic dermatitis

Takeaway

  • A cream formation containing hyaluronic acid 5% complexed with bacterial wall-derived glycoprotein and peptide glycan complex (EDS) is associated with clinical improvement of facial seborrheic dermatitis (SD).

Why this matters

  • The cream appears to improve clinical symptoms and equilibrate the facial bacterial microbiota.

Key results

  • EDS cream was associated with a 70% reduction in Investigator’s Global Assessment (IGA) score at week 3 (P=.001) and an 88% reduction at week 6 (P=.0001).
  • Scaling score was reduced 60% at week 3 and 86% at week 6 (no statistics shown).
  • Erythema score was reduced 57% at week 3 and 89% at week 6 (P=.001).
  • Treatment was associated with an increase in Cutibacterium and a reduction in Staphylococcus bacteria.
  • No local adverse effects were reported.

Study design

  • 75 patients with moderate to severe SD were treated with EDS cream twice daily, and analyzed for outcomes.
  • Funding: Cantabria Labs Difa Cooper.

Limitations

  • Small patient sample size.
  • No comparator.

References


YOU MAY ALSO LIKE